Important note

This AI stock analysis for Immunitybio is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Immunitybio - AI Stock Analysis

Analysis generated October 30, 2024

ImmunityBio is a clinical-stage immunotherapy company dedicated to developing next-generation cancer treatments. Focused on boosting the immune system to fight cancer, their comprehensive platform includes a number of novel immunotherapy treatments currently in various stages of development. The company leverages cutting-edge technology and research to drive forward the efficacy and safety of its innovative therapies.

Fundamental Analysis

ImmunityBio's revenue for the last quarter was $1M, which marks an impressive increase of 2,517.50% compared to the previous quarter. This substantial surge is a positive sign of growth and suggests that the company might be in an expansion phase. Year-over-year, this revenue increase is 2,453.66%, indicating robust annual growth.

On the profitability front, ImmunityBio's net income for the last quarter was $135M. This is a slight decrease of 0.34% from the previous quarter, which could be a point of concern. However, looking at the year-over-year comparison, there’s a 2.40% increase, which is a sign of long-term growth momentum.

The company’s EBITDA for the last quarter stood at $104M. This figure is slightly down by 0.14% from the previous quarter, showing a minor decline. Nonetheless, the year-over-year EBITDA increase of 0.83% suggests some positive improvement on an annual scale.

Technical Analysis

ImmunityBio's stock price is currently $5.64, an increase of 51.61% compared to a month ago, indicating a robust short-term upward trend. Over the past year, the stock price has risen by 79.62%, demonstrating sustained long-term growth and establishing a bullish trend.

The stock's Simple Moving Average (SMA10) is currently at 4.81, higher than the previous SMA10 of 4.60. This upward movement in the SMA indicates the potential for continued upward price momentum. The Relative Strength Index (RSI) is 60.4, which falls in a neutral zone, suggesting that the stock is neither overbought nor oversold, providing a balanced outlook.

Alternative Data Analysis

From the perspective of job postings and employee sentiment, ImmunityBio has 43 open positions, and this number has remained stable over the past few months, suggesting steady operations. However, the business outlook is down by 8%, which raises some concern about future expectations.

Regarding customer acquisition, ImmunityBio's website receives approximately 13,000 visitors, but this number has dropped by 50% in the past few months. This sharp decline might indicate a reduction in customer interest or engagement. Conversely, the company’s Twitter following has seen a 7% increase to 2,900 followers, indicating rising interest in the company's online presence.

According to AltIndex’s AI score, ImmunityBio has a score of 58, which signals a 'hold' recommendation. This balanced score reflects mixed signals from various fundamental, technical, and alternative data indicators.

Conclusion and Recommendation

In summary, ImmunityBio shows intriguing growth prospects with substantial increases in revenue and annual net income. However, there are signs of concern with slight declines in quarterly net income and EBITDA, along with a drop in user engagement on their website. The stock's strong short-term and long-term price trends, coupled with a rising interest on social media, offer a positive outlook. The neutral AI score indicates that the stock might be best held for now while monitoring closely for any shifts in the fundamental and alternative data trends.

Our recommendation based on the aggregate data would be to 'hold' ImmunityBio’s stock. While the company shows promising growth and remains in a bullish trend, certain declining metrics and user engagement warrant cautious optimism.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.